{"denoms":[{"counts":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"81"}],"units":"Participants"}],"groups":[{"description":"Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol (starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days was done if no ovarian response was observed) for maximum of 28 days received a single dose of 250 microgram (mcg) MSJ-0011 subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (\\>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of \\>=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).","id":"BG000","title":"MSJ-0011"},{"description":"Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol (starting dose of follitropin alfa as 75 IIU subcutaneously per day ,increments by 37.5 IU every 7 days was done if no ovarian response was observed) for maximum of 28 days received a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of \\>=18 mm; not more than 3 follicles each with a mean diameter of \\>=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.","id":"BG001","title":"Urinary Human Chorionic Gonadotropin (u-hCG)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.303","value":"32.61"},{"groupId":"BG001","spread":"3.603","value":"30.67"},{"groupId":"BG002","spread":"3.506","value":"31.96"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"81"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Safety population included all the subjects who received investigational medicinal product (\\[IMP\\]; MSJ-0011 or u-hCG)"}